{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-004313","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.627257+00:00","generated_at":"2026-05-27T01:15:34.292048+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arrowhead appoints Sarepta CEO Douglas Ingram as director","bullets":["Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.","Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.","He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.","Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-004313","json":"https://secwatch.observer/filing/0001628280-25-004313.json","markdown":"https://secwatch.observer/filing/0001628280-25-004313.md","text":"https://secwatch.observer/filing/0001628280-25-004313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/0001628280-25-004313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/arwr-20250207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:15:34.292048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7a151806f","claim":"Douglas Ingram was appointed as director at ARROWHEAD PHARMACEUTICALS, INC..","evidence_excerpt":"On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/0001628280-25-004313-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}